-
1.发明申请METHODS FOR MONITORING EFFECTIVENESS OF INTERFERON THERAPY IN INDIVIDUALS WITH HCV INFECTIONS 审中-公开监测HCV感染个体干扰素治疗效果的方法
公开(公告)号：WO1994004922A1
公开(公告)日：1994-03-03
申请号：PCT/US1993007287
申请日：1993-08-03
Applicant: ABBOTT LABORATORIES
Inventor： ABBOTT LABORATORIES , LENNARTZ, LIESELOTTE , MICHEL, Gerd , METHTA, Smriti, U. , TASKAR, Suhas , CLEMENS, John, M. , MIMMS, Larry, T. , CHAU, Kurt, H. , VALLARI, David, S.
IPC: G01N33/576
CPC classification number: G01N33/5767 , G01N2800/52
Abstract: A means for determining the effectiveness of interferon therapy in individuals who are infected with Hepatitis C Virus (HCV) and are receiving such therapy. Monitoring the level of anti-HCV IgM and/or anti-GOR IgG provide means for establishing whether or not the infected patient is responding to interferon therapy; such monitoring is especially useful for patients diagnosed with chronic acute HCV infections.
Abstract translation: 用于确定感染丙型肝炎病毒（HCV）并正在接受此类治疗的个体中干扰素治疗的有效性的方法。 监测抗HCV IgM和/或抗GOR IgG的水平提供了确定受感染的患者是否响应干扰素治疗的手段; 这种监测对于诊断为慢性急性HCV感染的患者特别有用。
-
2.发明公开METHODS FOR MONITORING EFFECTIVENESS OF INTERFERON THERAPY IN INDIVIDUALS WITH HCV INFECTIONS 失效监测方法干扰素治疗丙肝的有效性感染INDIVIDUREN。
公开(公告)号：EP0656116A1
公开(公告)日：1995-06-07
申请号：EP93919871.0
申请日：1993-08-03
Applicant: ABBOTT LABORATORIES
Inventor： LENNARTZ, LIESELOTTE , MICHEL, Gerd , METHTA, Smriti, U. , TASKAR, Suhas , CLEMENS, John, M. , MIMMS, Larry, T. , CHAU, Kurt, H. , VALLARI, David, S.
CPC classification number: G01N33/5767 , G01N2800/52
Abstract: A means for determining the effectiveness of interferon therapy in individuals who are infected with Hepatitis C Virus (HCV) and are receiving such therapy. Monitoring the level of anti-HCV IgM and/or anti-GOR IgG provide means for establishing whether or not the infected patient is responding to interferon therapy; such monitoring is especially useful for patients diagnosed with chronic acute HCV infections.
-
3.发明公开IgG/IgM RATIO FOR DETERMINING EFFECTIVENESS OF INTERFERON THERAPY IN INDIVIDUALS WITH HCV INFECTIONS 无效IGG / IGM RATIO用于确定干扰素治疗的有效性在单与HCV感染
公开(公告)号：EP0848821A1
公开(公告)日：1998-06-24
申请号：EP95923250.0
申请日：1995-06-07
Applicant: ABBOTT LABORATORIES
Inventor： BRAUN, Hans-Bertram , MICHEL, Gerd
IPC: G01N33
CPC classification number: G01N33/5767 , G01N2800/52
Abstract: A means for determining the effectiveness of interferon therapy for individuals receiving such therapy for HCV infections. Assaying for the presence of anti-HCV IgG and anti-HCV IgM and determining a ratio of the pre-interferon therapy amount of anti-HCV IgG to the pre-interferon therapy amount of anti-HCV IgM provide means for indicating the likelihood of an individual's response to interferon therapy.
-
4.发明授权IgG/IgM RATIO FOR DETERMINING EFFECTIVENESS OF INTERFERON THERAPY IN INDIVIDUALS WITH HCV INFECTIONS 无效IGG / IGM RATIO用于确定干扰素治疗的有效性在单与HCV感染
公开(公告)号：EP0848821B1
公开(公告)日：1999-10-27
申请号：EP95923250.5
申请日：1995-06-07
Applicant: ABBOTT LABORATORIES
Inventor： BRAUN, Hans-Bertram , MICHEL, Gerd
IPC: G01N33/576
CPC classification number: G01N33/5767 , G01N2800/52
Abstract: A means for determining the effectiveness of interferon therapy for individuals receiving such therapy for HCV infections. Assaying for the presence of anti-HCV IgG and anti-HCV IgM and determining a ratio of the pre-interferon therapy amount of anti-HCV IgG to the pre-interferon therapy amount of anti-HCV IgM provide means for indicating the likelihood of an individual's response to interferon therapy.
-
-
-
Search Results
4
records
(took 0.017 seconds)
